Section Arrow
Quote
LEXX.NASDAQ
- Lexaria Bioscience Corp
(Financial Status)
Quotes are at least 15-min delayed:2026/02/19 19:30 EST
After Hours
Last
 0.66
+0.0002 (+0.03%)
Bid
0.64
Ask
0.6597
High 0.66 
Low 0.6598 
Volume 4 
Regular Hours (Closed)
Last
 0.6598
-0.0002 (-0.03%)
Day High 
0.6671 
Prev. Close
0.66 
1-M High
0.8576 
Volume 
114.16K 
Bid
0.64
Ask
0.6597
Day Low
0.6378 
Open
0.6671 
1-M Low
0.6 
Market Cap 
16.43M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.67 
20-SMA 0.73 
50-SMA 0.76 
52-W High 1.8955 
52-W Low 0.46 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.57/-0.31
Enterprise Value
16.50M
Balance Sheet
Book Value Per Share
0.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
705.92K
Operating Revenue Per Share
0.01
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.1967+0.0047+2.45%0.09PE
After Hours 0.188 -0.0087 -4.42%
IBRXImmunityBio8.61+0.07+0.82%-- 
After Hours 8.46 -0.15 -1.74%
DRMADermata Therapeutics Inc1.93+0.65+50.78%0.08PE
After Hours 1.81 -0.12 -6.22%
QNCXQuince Therapeutics0.1622-0.0158-8.88%-- 
After Hours 0.1616 -0.0006 -0.37%
LIMNLiminatus Pharma Inc0.2383-0.0066-2.69%-- 
After Hours 0.235 -0.0033 -1.38%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.